Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
 
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size


 
Table of Contents   
ORIGINAL ARTICLE
Year : 2011  |  Volume : 6  |  Issue : 1  |  Page : 11-16
Evaluation of mediastinal lymph nodes using 18 F-FDG PET-CT scan and its histopathologic correlation


1 Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, India
2 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India
3 Department of Medicine, All India Institute of Medical Sciences, New Delhi, India
4 Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

Date of Submission03-May-2010
Date of Acceptance14-Jul-2010
Date of Web Publication28-Dec-2010

Correspondence Address:
Arvind Kumar
Department of Surgical Disciplines, AIIMS, New Delhi - 110 029
India
Login to access the Email id


DOI: 10.4103/1817-1737.74270

PMID: 21264165

Rights and Permissions

   Abstract 

Aims and Objectives: To determine the efficacy of integrated 18 F-fluorodeoxy glucose positron emission tomography-computed tomography ( 18 F-FDG PET-CT) in the evaluation and characterization of mediastinal lymph nodes into benign and malignant pathology.
Methods: Thirty-five patients with mediastinal lymphadenopathies without primary neoplastic or infective lung pathologies were included in the study. The lymph nodes were detected on contrast-enhanced CT scan of the chest. All patients underwent 18 F-FDG PET-CT scan for evaluation of mediastinal lymph nodes. Results of PET-CT were compared with histopathology of the lymph nodes and sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated.
Statistical Analysis: The data were collected prospectively and analyzed using (SPSS Inc., Chicago, IL) 11.5 software.
Results: Histopathology results in 35 patients revealed tuberculosis in 12, sarcoidosis in 8, and lymphoma in 15. Maximum standardized uptake value (SUVmax) of the benign lymph nodes ranged from 2.3 to 11.8 with a mean±standard deviation (SD) of 5.02±3.26. SUVmax of the malignant lymph nodes ranged from 2.4 to 34 with a mean±SD of 10.8±8.12. There was a statistically significant difference between benign and malignant pathology (P<0.0059). 18 F-FDG PET-CT has sensitivity of 93% and specificity of 40% with SUVmax 2.5 as the cutoff. We found the optimal SUVmax cutoff to be 6.2 as determined by the receiver-operator characteristic curve. With 6.2 as cutoff, the sensitivity, specificity, and accuracy were 87%, 70%, and 77%, respectively.
Conclusion : In countries where tuberculosis and other granulomatous diseases are endemic, SUVmax cutoff value of 2.5 has low specificity. Increasing the cutoff value can improve the specificity, while maintaining an acceptable sensitivity.


Keywords: FDG PET-CT, lymphoma, mediastinal lymph nodes, tuberculosis, sarcoidosis


How to cite this article:
Kumar A, Dutta R, Kannan U, Kumar R, Khilnani GC, Gupta SD. Evaluation of mediastinal lymph nodes using 18 F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med 2011;6:11-6

How to cite this URL:
Kumar A, Dutta R, Kannan U, Kumar R, Khilnani GC, Gupta SD. Evaluation of mediastinal lymph nodes using 18 F-FDG PET-CT scan and its histopathologic correlation. Ann Thorac Med [serial online] 2011 [cited 2019 Aug 19];6:11-6. Available from: http://www.thoracicmedicine.org/text.asp?2011/6/1/11/74270


Enlarged mediastinal lymph nodes is a common clinical condition encountered by Chest physicians. In the majority of clinical situations, we encounter multiple lymph node enlargements but rarely isolated lymphadenopathy is also encountered. Lymph nodes may be enlarged due to a variety of inflammatory, infectious, or malignant reasons. Hence, it is important to establish a diagnosis and differentiate benign from malignant lymph nodes. Computed tomography (CT) and magnetic resonance imaging (MRI) have been the standard imaging tools for evaluation of enlarged mediastinal lymph nodes, which have their own limitations. CT has low sensitivity (64%) and specificity (62%) in detecting malignant lymph nodes and it makes formal lymph node sampling by mediastinoscopy, thoracoscopy, or thoracotomy necessary to detect metastases. [1] MRI can overlook calcification in lymph nodes and label such enlarged lymph nodes as metastatic deposits. MRI has poor spatial resolution and as a result of that, a group of discrete, adjacent, normal-sized nodes appears as a single large nodal mass, which may be erroneously misdiagnosed as metastatic disease. [2] Although CT and MRI provide good structural details, their diagnostic criteria of size of 1 cm or more for abnormality can overlook microscopic metastases or partial infiltration of the node. 18 F-Fluorodeoxy glucose positron emission tomography ( 18 F-FDG-PET) can detect physiologic and biochemical processes in the body noninvasively. FDG-PET has high sensitivity (84%) and specificity (89%) in detecting malignant pathology in mediastinal lymph nodes in patients of lung cancer. [3] However, FDG-PET alone has limitation of poor localization of abnormal FDG metabolism. It has been reported that CT or PET alone may provide misdiagnosis in differentiating benign from malignant lymph nodes in a substantial proportion of patients. Combined PET-CT has been found to overcome limitations of CT or PET alone as it provides structural and functional information of disease status in the samesetting. [4] Most of the published studies from developed countries have shown high sensitivity and specificity when maximum standardized uptake value (SUVmax) of 2.5 was used as the cutoff value to differentiate benign from malignant conditions. However, these high diagnostic values of PET and PET-CT cannot be extrapolated to countries where mediastinal lymph node involvement due to granulomatous diseases is common. Hence, the present prospective study was planned to explore the role of 18 F-FDG PET-CT scan in the evaluation of mediastinal lymphadenopathies with no primary neoplastic or infective lung pathology in a population in which infective and inflammatory diseases in the mediastinum are common.


   Methods Top


This prospective observational study was carried out in a tertiary care referral hospital after approval from the Institutional Ethical Committee. Thirty-five patients with mediastinal lymphadenopathy detected on contrast-enhanced CT chest with no evidence of primary neoplastic or infective lung pathology were included in this study. There were 23 males and 12 females with mean age of 42.74 years. Characteristics of these patients are provided in [Table 1]. All the patients underwent combined 18 F-FDG PET-CT scan for evaluation of mediastinal lymphadenopathies. Results of PET-CT were compared with histopathology, which was considered as "gold standard" and sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET-CT were calculated.
Table 1 :Clinical, histology, and 18F-FDG PET-CT imaging characteristics of the patients


Click here to view


18 F-FDG-PET-CT scan protocol

All the patients were asked to come for PET-CT with at least 4-h fasting. None of our patients were diabetic. The images were obtained on a dedicated PET-CT scanner (Siemens, Biograph-2), 60 min after intravenous injection of 370 MBq of 18 F-FDG. CT acquisition was performed on spiral dual-slice CT with a slice thickness of 4 mm and a pitch of 1. Image was acquired using a matrix of 512Χ512 pixels and a pixel size of 1 mm. After transmission scan, three-dimensional (3D) PET acquisition was done for 3 min per bed position for 5-6 bed positions. PET data were acquired using matrix of 128Χ128 pixels with a slice thickness of 1.5 mm. CT-based attenuation correction of the emission images was employed. PET images were reconstructed by iterative method ordered subset expectation maximization (2 iterations and 8 subsets) with a filter size of 5 mm in this study. After completion of PET acquisition, the reconstructed attenuation corrected PET images, CT images, and fused images of matching pairs of PET and CT images were available for review in axial, coronal, and sagittal planes and in maximum intensity projections, 3D cine mode.

Image analysis

Attenuation corrected and uncorrected images were displayed on the monitor. Both the attenuation corrected and uncorrected images were visually analyzed for abnormal FDG uptake by an observer who had more than 3 years experience of reading PET-CT. After image reconstruction, a region of interest (ROI) consisting of 9Χ9 mm was carefully drawn on the consecutive 4-6 PET slices. From these ROIs, SUVmax was calculated according to the formula described below:

Mean ROI activity (MBq/g)Χbody weight (g)/injected dose (MBq/g)

(MBq = a mega-Becquerel, and g = grams).

For determination of lymph node size, maximum diameter in one plane was used on CT images. In case of multiple lymph node involvement, largest node was considered for size evaluation.

Histopathologic diagnosis

The histopathologic diagnosis was established in all the patients by any one of the following methods: peripheral lymph node biopsy, image-guided, mediastinoscopic, transbronchial, or mediastinal lymph node biopsy.

Statistical analysis

The histopathologic diagnosis was considered the gold standard. The PET-CT data were expressed as mean (SS) and or median (range) as applicable. Qualitative and quantitative data were compared by Chi-square test, Student's t test, Mann-Whitney U test, or analysis of variance as appropriate. A P value of <0.05 was considered significant. The sensitivity, specificity, PPV, NPV, and accuracy of PET-CT to differentiate benign and malignant lesions were calculated. A receiver-operator characteristic (ROC) curve was drawn to find out a cutoff value of SUV at which sensitivity and specificity are highest.


   Results Top


Of the 35 patients, 20 were found to have benign, whereas 15 had malignant pathologies on histopathology. Among the 20 benign pathologies, 12 were tuberculosis [Figure 1] and 8 were sarcoidosis [Figure 2]. All the 15 patients in the malignant group had lymphoma [Figure 3]. The SUVmax of the benign nodes ranged from 2.3 to 11.8 with a mean±SD of 5.02±3.26. The SUVmax of the malignant nodes ranged from 2.4 to 34 with a mean±SD of 10.8±8.12. There was a statistically significant difference between benign and malignant pathology (P<0.0059) by Mann-Whitney U test. Similarly, average standardized uptake value (SUVavg) of the benign nodes ranged from 1.1 to 4.7 with the mean±SD of 2.3±1.28. The SUVavg of the malignant nodes ranged from 1.2 to 15 with the mean±SD of 4.59±4.24. There was a statistically significant difference between benign and malignant pathology (P<0.01) by Mann-Whitney U test. [Table 1] shows the results of PET-CT scan with their histopathologic diagnosis. Among the benign pathologies, the SUVmax ranged from 2.4 to 10.9 with a mean±SD of 4.6±3.2 in sarcoidosis, while in tuberculosis the SUVmax ranged from 2.3 to 11.8 with a mean±SD of 5.3±3.4. The SUVavg in sarcoidosis ranged from 1.1 to 4.7 with a mean±SD of 2.2±1.36. The SUVavg in tuberculosis ranged from 1.2 to 4.4 with a mean±SD of 2.4±1.3. The difference in SUV max and average standardized uptake value (SUVavg) between 2 benign conditions was not statistically significant. The SUVmax and SUVavg were found to be correlating well with the size of benign mediastinal lymph node, but it was not statistically significant [Figure 4] and [Figure 5].
Figure 1 :Axial CT, PET, and PET-CT images showing increased FDG uptake in mediastinal lymph nodes in a patient having tuberculosis

Click here to view
Figure 2 :Axial CT, PET, and PET-CT images showing increased FDG uptake in mediastinal lymph nodes in a patient having sarcoidosis

Click here to view
Figure 3 :Axial CT, PET, and PET-CT images showing increased FDG uptake in mediastinal lymph nodes and left internal mammary lymph nodes in a patient having lymphoma

Click here to view
Figure 4 :The maximum and average SUV correlation with the size of the mediastinal lymph nodes in tuberculosis

Click here to view
Figure 5 :The maximum and average SUV correlation with the size of the mediastinal lymph nodes in sarcoidosis

Click here to view


The SUVmax was used for discrimination between benign and malignant lymph nodes. We evaluated the efficacy of PET-CT at different cutoff values of SUVmax after reconstruction of a 4Χ4 table for each value. When 2.5 was used as the cutoff value, the sensitivity, specificity, PPV, NPV, and accuracy were 93%, 40%, 54%, 89%, and 63% respectively. With SUVmax of 5.3 as the cutoff as reported by Lee et al., for non-small cell lung cancer, the specificity in our study increased to 65% from 40% with no significant change in sensitivity, which decreased from 93% to 87%. In addition, accuracy also improved from 63% to 74%. We found the optimal SUVmax cutoff to be 6.2 as determined by the ROC curve analysis [Figure 6]. SUVmax of 6.2 as the cutoff value, the sensitivity, specificity, and accuracy were 87%, 70%, and 77%, respectively [Table 2].
Table 2 :Efficacy of PET-CT at various cutoffs in differentiating benign from malignant mediastinal lymph nodes


Click here to view
Figure 6 :Receiver-operator characteristic curve to find out theoptimal SUVmax cutoff value

Click here to view



   Discussion Top


Mediastinal lymph node enlargements are caused most often by lymphoma, metastatic carcinoma, sarcoidosis, and infection, either directly by organisms, such as Mycobacterium tuberculosis, Histoplasma capsulatum, and others, or as a hyperplastic reaction to the presence of organisms within the lungs. [5],[6],[7],[8],[9],[10] Noninvasive tests, such as CT and MRI have a limited role in differentiating malignant from benign lymph node due to lack of specific clinical parameters. Mediastinal lymph node staging has important therapeutic and prognostic implications in lung cancer. Patients without lymph node involvement are treated with surgery alone, whereas others with gross mediastinal lymphadenopathy are treated with definitive chemotherapy and radiotherapy. [11],[12]

Distinction between benign and malignant involvement in isolated mediastinal lymph node requires invasive modalities, such as image-guided biopsy (CT, endoscopic ultrasound), transbronchial lymph node biopsy, or thoracoscopic or mediastinoscopic biopsy. Being invasive, each has its own list of complications. 18 F-FDG PET-CT, a recently introduced noninvasive imaging modality, has been included in the staging of lymphoma and has been found to have higher sensitivity than CT. [13] However, FDG is not specific for detecting malignant conditions. It has been shown that inflammatory cells also show avidity for FDG. [14]

The SUVmax has been reported to be an independent predictor of malignancy and lymph node metastasis. [11] SUVmax is preferred over SUVavg as there is a variability of about 35% between observers when SUVavg is used and this reduces to 3% when SUVmax is used. [15] The SUVmax cutoff value of 2.5 is used commonly to differentiate between benign and malignant lesions. [16] A retrospective study from South Korea on focal abnormalities in pulmonary parenchyma showed that 90% of the tuberculoma showed SUVmax uptake above 2.5, thus supporting the need to increase the cutoff value to differentiate benign and malignant lesions. [17] We also observed similar results. There is a significant overlap in the SUVmax between benign and malignant conditions when SUV of 2.5 was used as the cutoff limit. In our study, there were 12 patients of benign condition with SUVmax more than 2.5. The sensitivity and specificity in our study was 93% and 40%, respectively, with 2.5 as the cutoff value. The low specificity observed with the cutoff of 2.5 could be due to high prevalence of inflammatory diseases in our patient population. Twenty of our cases (57%) were either tuberculosis or sarcoidosis.

In our study, highest SUVmax in patients of tuberculosis and sarcoidosis was 11.8 and 10.9, respectively. Similar higher values of SUVmax have been reported in the literature. [18] Lee et al. studied 110 patients of lung cancer to find out the utility of SUVmax in predicting malignancy in mediastinal lymph nodes using FDG PET-CT. Authors opined that SUVmax of 5.3 as cutoff increases the specificity from 86% to 98% and accuracy from 87% to 97%. In this study, the specificity increased from 40% to 65% when cutoff SUV was increased from 2.5 to 5.3. [11] However, in the present study, the best cutoff value with optimal sensitivity and specificity as determined by the ROC curve was 6.2. We found a sensitivity, specificity, and accuracy of 87%, 70%, and 77%, respectively, with SUVmax cutoff value of 6.2.


   Conclusion Top


The conventional SUVmax of 2.5 to differentiate benign and malignant lesions may not provide significant specificity in the developing countries where tuberculosis and sarcoidosis are common. Increasing the cutoff values can improve the specificity, while maintaining an acceptable sensitivity. A study incorporating large number of patients is needed to confirm our initial results.

 
   References Top

1.McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992;182:319-23.  Back to cited text no. 1
[PUBMED]  [FULLTEXT]  
2.Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small cell carcinoma of the lung: imaging methods. AJR Am J Roentgenol 1995;164:1349-59.  Back to cited text no. 2
[PUBMED]  [FULLTEXT]  
3.Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer a review of the current evidence. Chest 2003;123;137S-46S.  Back to cited text no. 3
    
4.Liu Q, Peng ZM, Liu QW, Yao SZ, Zhang L, Meng L, et al. The role of 11C-choline positron emission tomography-computed tomography and videomediastinoscopy in the evaluation of diseases of middle mediastinum. Chin Med J 2006;119:634-9.  Back to cited text no. 4
[PUBMED]  [FULLTEXT]  
5.Fraser RS, Mόller NL, Colman N, Pare PD. Fraser and Pare's Diagnosis of Diseases of the Chest. 4 th ed. Philadelphia: 1999. p. 2938-73.   Back to cited text no. 5
    
6.McLoud TC, Meyer JE. Mediastial metastases. Radiol Clin North Am 1982;20:453-68.  Back to cited text no. 6
[PUBMED]    
7.Filly R, Bland N, Castellino RA. Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin's disease and non-Hodgkin's lymphoma. Radiology 1976;120:277-81.  Back to cited text no. 7
[PUBMED]    
8.Choyke PL, Sostman HD, Curtis AM, Ravin CE, Chen JT, Godwin JD, et al. Adult-onset pulmonary tuberculosis. Radiology 1983;148:357-62.  Back to cited text no. 8
[PUBMED]  [FULLTEXT]  
9.Berkmen YM. Radiologic aspects of intrathoracic sarcoidosis. Semin Roentgenol 1985;20:356-75.  Back to cited text no. 9
[PUBMED]    
10.Waldron JA Jr, Dohring EJ, Farber LR. Primary large cell lymphomas of the mediastinum: an analysis of 20 cases. Semin Diagn Pathol 1985;2:281-95.  Back to cited text no. 10
[PUBMED]    
11.Lee BE, Redwine J, Foster C, Abella E, Lown T, Lau D, et al. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. J Thorac Cardiovasc Surg 2008;135:615-9.  Back to cited text no. 11
[PUBMED]  [FULLTEXT]  
12.Lewis PJ, Salama A. Uptake of Fluorine- 18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 1994;35:1647-9.  Back to cited text no. 12
[PUBMED]  [FULLTEXT]  
13.Altamirano J, Esparza JR, de la Garza Salazar J, Calvo PS, Vera SR, Chalapud Revelo JR, et al. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Arch Med Res 2008;39:69-77.  Back to cited text no. 13
[PUBMED]  [FULLTEXT]  
14.Kumar R, Basu S, Torigian D, Anand V, Zhuang H, Alavi A. Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev 2008;21:209-24.  Back to cited text no. 14
[PUBMED]  [FULLTEXT]  
15.Cerfolio RJ, Bryant AS. Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with non small-cell lung cancer. Ann Thorac Surg 2007;83:1826-1830.  Back to cited text no. 15
[PUBMED]  [FULLTEXT]  
16.Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982-8.  Back to cited text no. 16
[PUBMED]  [FULLTEXT]  
17.Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216:117-21.  Back to cited text no. 17
[PUBMED]  [FULLTEXT]  
18.Teirstein AS, Machac J, Almeida O, Lu P, Padilla ML, Iannuzzi MC. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007;132:1949-53.  Back to cited text no. 18
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
 
 
    Tables

  [Table 1], [Table 2]

This article has been cited by
1 Prone-position thoracoscopic resection of posterior mediastinal lymph node metastasis from rectal cancer
Yasuhiro Shirakawa,Kazuhiro Noma,Takeshi Koujima,Naoaki Maeda,Shunsuke Tanabe,Toshiaki Ohara,Toshiyoshi Fujiwara
World Journal of Surgical Oncology. 2015; 13(1)
[Pubmed] | [DOI]
2 The Applications of Corrected Standardized Uptake Values in the Diagnosis of Peripheral Lung Lesions
Ming Ming,Zhen G. Wang,DaCheng Li,FengYu Wu,SiMin Liu,Bin Shi,Wei Xue
Medicine. 2015; 94(6): e531
[Pubmed] | [DOI]
3 18F-FDG and 18F-FLT PET/CT imaging in the characterization of mediastinal lymph nodes
Sampanna Jung Rayamajhi,Bhagwant Rai Mittal,Venkata Nagarjuna Maturu,Ritesh Agarwal,Amanjit Bal,Pranab Dey,Jaya Shukla,Dheeraj Gupta
Annals of Nuclear Medicine. 2015;
[Pubmed] | [DOI]
4 Kikuchi-Fujimoto disease associated with community acquired pneumonia showing intrathoratic lymphadenopathy without cervical lesions
Nobuhito Naito,Tsutomu Shinohara,Hisanori Machida,Hiroyuki Hino,Keishi Naruse,Fumitaka Ogushi
SpringerPlus. 2015; 4(1)
[Pubmed] | [DOI]
5 Sarcoidosis misdiagnosed as malignant tumors: a case report
Zuosheng Li,Xin Li,Zuoqing Song,Jinghao Liu,Ming Dong,Tao Shi,Dian Ren,Song Xu,Jun Chen
World Journal of Surgical Oncology. 2015; 13(1)
[Pubmed] | [DOI]
6 Mediastinal Seminoma with an Elevated Level of Serum Angiotensin-converting Enzyme
Hiroshi Ishii,Fumiyasu Igata,Kazuki Nabeshima,Hisako Kushima,Kentaro Watanabe
Internal Medicine. 2015; 54(15): 1909
[Pubmed] | [DOI]
7 Dual-Time Point Whole-Body18F-Fluorodeoxyglucose PET/CT Imaging in Undiagnosed Mediastinal Lymphadenopathy
Venkata Nagarjuna Maturu,Ritesh Agarwal,Ashutosh Nath Aggarwal,Bhagwant Rai Mittal,Amanjit Bal,Nalini Gupta,Dheeraj Gupta
Chest. 2014; 146(6): e216
[Pubmed] | [DOI]
8 Anatomical and histopathological airway abnormalities detected during fiberoptic bronchoscopy in patients with mediastinal lymphadenopathy
K. Eid,H. Khatab,S. Ahmed,G. Saad
Egyptian Journal of Chest Diseases and Tuberculosis. 2014;
[Pubmed] | [DOI]
9 result 4 Document Multicentric Castlemanæs disease: Closest mimic of lymphoma on FDG PET/CT
Puranik, A.D., Purandare, N.C., Shah, S., Agrawal, A., Rangarajan, V.
Source of the Document Indian Journal of Nuclear Medicine. 2013;
[Pubmed]
10 Non-neoplastic bulky mediastinal mass presentation in an adolescent patient: a case report
Paula Blatyta,Claudio Borba,Ligia de Queiroz,Raphael Salles de Medeiros,Fabiana de Campos,Israel Bendit
Journal of Medical Case Reports. 2013; 7(1): 233
[Pubmed] | [DOI]
11 Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT
Ah Young Lee,Su Jung Choi,Kyung Pyo Jung,Ji Sun Park,Seok Mo Lee,Sang Kyun Bae
Nuclear Medicine and Molecular Imaging. 2013;
[Pubmed] | [DOI]
12 Heterogeneity Analysis of 18F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting
Hendra Budiawan,Gi Jeong Cheon,Hyung-Jun Im,Soo Jin Lee,Jin Chul Paeng,Keon Wook Kang,June-Key Chung,Dong Soo Lee
Nuclear Medicine and Molecular Imaging. 2013;
[Pubmed] | [DOI]
13 Primary nodal anthracosis identified by EBUS-TBNA as a cause of FDG PET/CT positive mediastinal lymphadenopathy
Richard J. Hewitt,Corrina Wright,David Adeboyeku,Dan Ornadel,Matthew Berry,Melissa Wickremasinghe,Andrew Wright,Annemarie Sykes,Onn Min Kon
Respiratory Medicine Case Reports. 2013; 10: 48
[Pubmed] | [DOI]
14 Tuberculous and non-tuberculous granulomatous lymphadenitis in patients receiving imatinibmesylate (glivec) for metastatic gastrointestinal stromal tumor
Agaimy, A. and Brueckl, V. and Schmidt, D. and Krieg, S. and Ullrich, E. and Meidenbauer, N.
Case Reports in Oncology. 2013; 6(1): 134-142
[Pubmed]
15 18F-FDG PET/CT in tuberculosis: An early non-invasive marker of therapeutic response
Martinez, V. and Castilla-Lievre, M.A. and Guillet-Caruba, C. and Grenier, G. and Fior, R. and Desarnaud, S. and Doucet-Populaire, F. and Boué, F.
International Journal of Tuberculosis and Lung Disease. 2012; 16(9): 1180-1185
[Pubmed]
16 Mediastinal lymphadenopathy in ampullary adenocarcinoma: Not always metastatic
Rao, C.A.S. and Rana, S.S. and Bhasin, D.K. and Nada, R. and Sampath, S. and Mittal, B.R. and Sharma, V. and Dhaliwal, H.S. and Singh, K.
Annals of Gastroenterology. 2012; 25(2): 167-169
[Pubmed]
17 PET/CT in patients with sarcoidosis or IgG4 disease
Yu, J.Q. and Doss, M. and Codreanu, I. and Zhuang, H.
PET Clinics. 2012; 7(2): 191-210
[Pubmed]
18 Incidental detection and monitoring of spontaneous recovery of sarcoidosis via fluorine-18-fluoroethyl-choline positron emission tomography/computed tomography
Takesch, M. and Haberkorn, U. and Strauss, L.G. and Roumia, S. and Dimitrakopoulou-Strauss, A.
Hellenic Journal of Nuclear Medicine. 2012; 15(1): 63-65+82
[Pubmed]
19 The evolving role of medical imaging in lymphoma management: The clinicianæs perspective
Svoboda, J. and Schuster, S.J.
PET Clinics. 2012; 7(1): 35-46
[Pubmed]
20 The Evolving Role of Medical Imaging in Lymphoma Management: The Clinician’s Perspective
Jakub Svoboda,Stephen J. Schuster
PET Clinics. 2012; 7(1): 35
[Pubmed] | [DOI]
21 PET/CT in Patients with Sarcoidosis or IgG4 Disease
Jian Q. Yu,Mohan Doss,Ion Codreanu,Hongming Zhuang
PET Clinics. 2012; 7(2): 191
[Pubmed] | [DOI]
22 Sarcoidosis and lymphoma: Case series and literature review
Maayan, H. and Ashkenazi, Y. and Nagler, A. and Izbicki, G.
Sarcoidosis Vasculitis and Diffuse Lung Diseases. 2011; 28(2): 146-152
[Pubmed]
23 False-positive mediastinal lymphadenopathy on 18F-fluorodeoxyglucose positron emission tomography and computed tomography after rectal cancer resection: A case report of thoracoscopic surgery in the prone position
Tsukada, T. and Nakano, T. and Matoba, M. and Sasaki, S. and Higashi, K.
Case Reports in Oncology. 2011; 4(3): 569-575
[Pubmed]



 

Top
Print this article  Email this article
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (1,096 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    Methods
    Results
    Discussion
    Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed10124    
    Printed331    
    Emailed3    
    PDF Downloaded940    
    Comments [Add]    
    Cited by others 23    

Recommend this journal